SCHEMBL6418247

SCHEMBL6418247

Cc1cc(O)c(C(=O)/C=C/c2cccn2-c2ccc(Cl)cc2)c(=O)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.65
KMT2A Q03164 12/20 0.65
USP2 O75604 3/20 0.65
POLB P06746 3/20 0.53
RAB9A P51151 5/20 0.52
NPC1 O15118 3/20 0.52
PPARG P37231 2/20 0.51
PKM P14618 3/20 0.49
NR3C1 P04150 1/20 0.49
MAPT P10636 6/20 0.48
NPSR1 Q6W5P4 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
RECQL P46063 2/20 0.48
PLIN1 O60240 1/20 0.48
ALOX12 P18054 1/20 0.48
PLIN5 Q00G26 1/20 0.48
ABHD5 Q8WTS1 1/20 0.48
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47
HTT P42858 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418251 1.00 MEN1 (0.65) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL6421527 0.93 MEN1 (0.60) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL6421523 0.93 MEN1 (0.60) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL6416568 0.74 MEN1 (0.56) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL6416910 0.73 MEN1 (0.69) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL6416917 0.73 MEN1 (0.69) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL10618560 0.72 MEN1 (0.76) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL10618566 0.72 MEN1 (0.76) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL1233090 0.71 PKM (0.47) MEN1KMT2AUSP2POLBRAB9A
SCHEMBL1233089 0.71 PKM (0.47) MEN1KMT2AUSP2POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861419-B2 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-03-01 US disclosed
EP-1324993-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2003-07-09 EP disclosed
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 US disclosed
WO-2001079187-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES CYTOVIA, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP14, CASP4 MEN1 2225/4885KMT2A 4221/4885USP2 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.